Database Query Results : Sorafenib (brand name Nexavar), ,

SRF, Sorafenib (brand name Nexavar): Click to Expand ⟱
Features: kinase inhibitor drug
Inhibitors of vascular endothelial growth factor receptor (VEGFR); used to treat kidney, liver and thyroid cancers.
Scientific Papers found: Click to Expand⟱
2423- 2DG,  SRF,    2-Deoxyglucose and sorafenib synergistically suppress the proliferation and motility of hepatocellular carcinoma cells
- in-vitro, HCC, NA
ChemoSen↑, TumCP↓, cycD1/CCND1↓, MMP9↓,
2424- 2DG,  SRF,    The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells
- in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7
ChemoSen↓, Glycolysis↓, HK1↓, HK2↓, ATP↓,
2572- ART/DHA,  SRF,    Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax
- in-vitro, AML, NA
CHOP↑, Mcl-1↓, ChemoSen↑, selectivity↑,
1361- Ash,  SRF,    Withaferin A, a natural thioredoxin reductase 1 (TrxR1) inhibitor, synergistically enhances the antitumor efficacy of sorafenib through ROS-mediated ER stress and DNA damage in hepatocellular carcinoma cells
- in-vitro, Liver, HUH7 - in-vivo, Liver, HUH7
TrxR↓, ROS↑, DNA-PK↑, ER Stress↑, Apoptosis↑, eff↓,
1320- EMD,  SRF,    Emodin Sensitizes Hepatocellular Carcinoma Cells to the Anti-Cancer Effect of Sorafenib through Suppression of Cholesterol Metabolism
- vitro+vivo, HCC, HepG2 - in-vitro, HCC, Hep3B - in-vitro, HCC, HUH7 - vitro+vivo, Hepat, SK-HEP-1
SREBF2↓, Akt↓, TumCCA↑, TumCG↓, STAT3↓,
1168- IVM,  SRF,    Ivermectin synergizes sorafenib in hepatocellular carcinoma via targeting multiple oncogenic pathways
- in-vitro, HCC, NA
TumMeta↓, mTOR↓, EMT↓, CSCsMark↓, STAT3↓,

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 6

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

HK1↓, 1,   ROS↑, 1,   TrxR↓, 1,  

Mitochondria & Bioenergetics ⓘ

ATP↓, 1,  

Core Metabolism/Glycolysis ⓘ

Glycolysis↓, 1,   HK2↓, 1,   SREBF2↓, 1,  

Cell Death ⓘ

Akt↓, 1,   Apoptosis↑, 1,   Mcl-1↓, 1,  

Protein Folding & ER Stress ⓘ

CHOP↑, 1,   ER Stress↑, 1,  

DNA Damage & Repair ⓘ

DNA-PK↑, 1,  

Cell Cycle & Senescence ⓘ

cycD1/CCND1↓, 1,   TumCCA↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

CSCsMark↓, 1,   EMT↓, 1,   mTOR↓, 1,   STAT3↓, 2,   TumCG↓, 1,  

Migration ⓘ

MMP9↓, 1,   TumCP↓, 1,   TumMeta↓, 1,  

Drug Metabolism & Resistance ⓘ

ChemoSen↓, 1,   ChemoSen↑, 2,   eff↓, 1,   selectivity↑, 1,  
Total Targets: 27

Pathway results for Effect on Normal Cells:


Total Targets: 0

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:16  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page